Opdivo And Eliquis Carry Bristol’s Q1; Company Continues To Defend IO Strategy

Novel oral anticoagulant Eliquis (apixaban) brought in $1.5bn in the first quarter and is set to overtake warfarin later this year. But Bristol remains on the defense on IO after a disappointing AACR.